Psychedelic Therapeutics for Adolescents: Safety, Opportunities, and Equipoise

We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution."¹ We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine. We agree that there is a compelling rationale for timely, rigorous studies with adolescents as it is likely that these compounds have been and will be used in adolescents with therapeutic intent. We are writing to catalyze further collegial dialogue and advocacy in our field. We do have some considerations for the authors.